16.24
Tandem Diabetes Care Inc stock is traded at $16.24, with a volume of 1.63M.
It is down -1.69% in the last 24 hours and down -7.36% over the past month.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
See More
Previous Close:
$16.52
Open:
$16.61
24h Volume:
1.63M
Relative Volume:
0.76
Market Cap:
$1.13B
Revenue:
$1.03B
Net Income/Loss:
$-94.55M
P/E Ratio:
-11.59
EPS:
-1.4012
Net Cash Flow:
$-3.64M
1W Performance:
+0.81%
1M Performance:
-7.36%
6M Performance:
-19.16%
1Y Performance:
+6.21%
Tandem Diabetes Care Inc Stock (TNDM) Company Profile
Name
Tandem Diabetes Care Inc
Sector
Industry
Phone
858-366-6900
Address
12400 HIGH BLUFF DRIVE, San Diego, CA
Compare TNDM vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
TNDM
Tandem Diabetes Care Inc
|
16.24 | 1.13B | 1.03B | -94.55M | -3.64M | -1.4012 |
|
ABT
Abbott Laboratories
|
104.89 | 181.50B | 46.59B | 5.41B | 7.38B | 3.0938 |
|
MDT
Medtronic Plc
|
94.75 | 121.20B | 36.36B | 4.84B | 5.43B | 3.7261 |
|
SYK
Stryker Corp
|
294.66 | 113.02B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
BSX
Boston Scientific Corp
|
44.39 | 64.33B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
86.60 | 49.92B | 6.30B | 1.07B | 1.09B | 1.8406 |
Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-26 | Initiated | Barclays | Equal Weight |
| Sep-30-26 | Reiterated | Citigroup | Neutral |
| Aug-21-26 | Initiated | William Blair | Outperform |
| Jul-28-26 | Resumed | UBS | Neutral |
| Jun-23-26 | Initiated | Deutsche Bank | Hold |
| Jun-01-26 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-12-26 | Initiated | The Benchmark Company | Hold |
| Mar-19-26 | Upgrade | Truist | Hold → Buy |
| Mar-17-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Feb-23-26 | Upgrade | Lake Street | Hold → Buy |
| Feb-20-26 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-27-26 | Resumed | TD Cowen | Buy |
| Dec-16-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-21-25 | Resumed | Stifel | Hold |
| Sep-08-25 | Initiated | Oppenheimer | Outperform |
| Aug-12-25 | Upgrade | Citigroup | Sell → Neutral |
| Aug-07-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-09-25 | Downgrade | Citigroup | Neutral → Sell |
| Jun-16-25 | Initiated | Truist | Hold |
| Apr-10-25 | Initiated | Mizuho | Neutral |
| Mar-05-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-04-25 | Downgrade | Citigroup | Buy → Neutral |
| Mar-03-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-28-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-02-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-06-24 | Initiated | Bernstein | Outperform |
| Oct-04-24 | Initiated | Goldman | Neutral |
| Oct-02-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-22-24 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-08-24 | Initiated | Canaccord Genuity | Buy |
| May-30-24 | Initiated | Redburn Atlantic | Buy |
| May-22-24 | Upgrade | Citigroup | Neutral → Buy |
| Apr-29-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-25-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Mar-26-24 | Upgrade | Stifel | Hold → Buy |
| Aug-04-23 | Downgrade | Citigroup | Buy → Neutral |
| May-05-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Apr-24-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-29-23 | Initiated | UBS | Neutral |
| Jan-26-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-15-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Aug-09-22 | Downgrade | Wells Fargo | Overweight → Underweight |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-25-21 | Initiated | Barclays | Underweight |
| Dec-15-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-20-20 | Initiated | Wells Fargo | Overweight |
| Jul-31-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jul-06-20 | Upgrade | Citigroup | Neutral → Buy |
| Jun-18-20 | Reiterated | Raymond James | Outperform |
| Apr-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Mar-23-20 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-05-20 | Initiated | Citigroup | Neutral |
| Feb-06-20 | Initiated | Raymond James | Outperform |
| Feb-04-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-18-19 | Initiated | Guggenheim | Buy |
| Oct-04-19 | Upgrade | UBS | Neutral → Buy |
| May-17-19 | Reiterated | BofA/Merrill | Neutral |
| May-13-19 | Initiated | SVB Leerink | Outperform |
| Mar-08-19 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-19 | Reiterated | BofA/Merrill | Neutral |
| Feb-27-19 | Reiterated | Lake Street | Buy |
| Nov-21-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-26-18 | Reiterated | Dougherty & Company | Buy |
| Sep-26-18 | Reiterated | Piper Jaffray | Overweight |
View All
Tandem Diabetes Care Inc Stock (TNDM) Latest News
Tandem Diabetes Care, Inc. (TNDM) Stock Forecasts - Yahoo Finance
Tandem Diabetes Care Q2 2026 Earnings Call Transcript - Benzinga
App Recall Might Change The Case For Investing In Tandem Diabetes Care (TNDM) - Simply Wall Street
Tandem Diabetes Care, Inc. (TNDM) Stock forecasts - Yahoo Finance Singapore
Is it the Right Time to Hold TNDM Stock in Your Portfolio? - Zacks Investment Research
Is it the Right Time to Hold TNDM Stock in Your Portfolio? - TradingView
Barclays Downgrades Tandem Diabetes Care(TNDM.US) to Hold Rating, Cuts Target Price to $18 - Moomoo
Tandem Diabetes Care, Inc. (TNDM) Stock Forecasts - Yahoo Finance
Barclays Keeps Their Hold Rating on Tandem Diabetes Care (TNDM) - The Globe and Mail
Tandem Diabetes Care, Inc. (TNDM) Stock Forecasts - Yahoo Finance
Tandem Diabetes Care, Inc. (0M0F.L) stock price, news, quote and history - Yahoo Finance Australia
RBC Capital Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $26 - Moomoo
Tandem Diabetes Care to Announce Third Quarter 2026 Financial Results on November 5, 2026 - Business Wire
Tandem Diabetes Care (NasdaqGM:TNDM) Stock Forecast & Analyst Predictions - Simply Wall Street
Tandem Diabetes Care, Inc. (TNDM) Stock Forecasts - Yahoo Finance
Tandem Diabetes Care (TNDM) Is Up 7.2% After International Launch Of Mobi Insulin Pump System - Yahoo Finance
Q2 Earnings Highlights: Tandem Diabetes (NASDAQ:TNDM) Vs The Rest Of The Healthcare Technology Stocks - Yahoo Finance
Operating cash flow per share of Tandem Diabetes Care, Inc. – HAN:TD5A - tradingview.com
Tandem Diabetes Care, Inc. (0M0F.L) Stock Price, News, Quote & History - Yahoo! Finance Canada
Tandem Diabetes (TNDM) Expands Mobi Insulin Delivery System to 1 - GuruFocus
Tandem Diabetes Expands Insulin Delivery System to 12 New Countries - Moomoo
Tandem Diabetes Expands Insulin Delivery System to 12 New Countries - Yahoo Finance
Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets - News-Press NOW
Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets - Yahoo Finance
Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets - Business Wire
Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets - Nasdaq
Tandem Diabetes Care, Inc. (TNDM) Stock Forecasts - Yahoo! Finance Canada
A Look at Tandem Diabetes Care Inc (TNDM) After 3.3% Gain -- GF Value $24.10 vs Price $15.72 - GuruFocus
Tandem Diabetes Care, Inc. (TNDM) Stock Forecasts - Yahoo Finance
Truist Lowers Price Target on Tandem Diabetes Care to $28 From $31, Keeps Buy Rating - marketscreener.com
Truist Lowers Price Target on Tandem Diabetes Care to $28 From $31, Keeps Buy Rating - Yahoo Finance
Tandem Diabetes Care, Inc. (TNDM) Stock Forecasts - finance.yahoo.com
Surgery Partners, 10x Genomics, QuidelOrtho, Zimmer Biomet, and Tandem Diabetes Stocks Trade Down, What You Need To Know - Yahoo Finance
A Look at Tandem Diabetes Care Inc (TNDM) After 6.4% Decline -- GF Value $24.09 vs Price $16.38 - GuruFocus
Tandem Diabetes Care, Inc. (TNDM) Stock Analysis: Exploring a 62.88% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
Tandem Diabetes Care, Inc. (TNDM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Is Tandem Diabetes Care (TNDM) Undervalued As Investors Weigh Its 34% One Year Return? - Yahoo Finance
Officer at Tandem Diabetes Care (NASDAQ: TNDM) plans 360-share stock sale - Stock Titan
Tandem Diabetes Care (TNDM) Soars 7.7%: Is Further Upside Left in the Stock? - Yahoo Finance
A Look at Tandem Diabetes Care Inc (TNDM) After 7.7% Gain -- GF Value $24.08 vs Price $17.54 - GuruFocus
Tandem Diabetes Care, Inc. (TNDM) Stock Forecasts - Yahoo Finance
(TNDM) Volatility Zones as Tactical Triggers - Stock Traders Daily
Tandem Diabetes Care: Stop Paying For Tomorrow's ProfitsStrong Sell (NASDAQ:TNDM) - Seeking Alpha
Is Tandem Diabetes Care Inc (TNDM) a Bargain After 4.2% Drop? GF Value Says Undervalued - GuruFocus
Is Tandem Diabetes Care Inc (TNDM) a Bargain After 4.2% Drop? GF Value Says Undervalued - GuruFocus
Zacks Investment Research - גלובס
Reasons to Retain Tandem Diabetes Stock in Your Portfolio Now - Yahoo Finance
(TNDM) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
A Look at Tandem Diabetes Care Inc (TNDM) After 3.4% Decline -- GF Value $24.05 vs Price $20.56 - GuruFocus
Tandem Diabetes Care stock gains after recent rally in diabetes tech - ad-hoc-news.de
Tandem Diabetes Care Inc Stock (TNDM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tandem Diabetes Care Inc Stock (TNDM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MARK NOVARA | Officer |
Aug 18 '26 |
Proposed Sale |
22.26 |
131 |
2,915 |
0 |
| Kyrillos Jean-Claude | EVP & Chief Operating Officer |
Aug 15 '26 |
Option Exercise |
0.00 |
1,010 |
0 |
30,825 |
| Gasser Elizabeth Anne | EVP, Chief Strategy Officer |
Aug 15 '26 |
Option Exercise |
0.00 |
3,014 |
0 |
2,425 |
| Carpenter Rick | EVP & Chief Technology Officer |
Aug 15 '26 |
Option Exercise |
0.00 |
2,507 |
0 |
32,968 |
| Hansen Shannon Marie | EVP & Chief Legal Officer |
Aug 15 '26 |
Option Exercise |
0.00 |
3,014 |
0 |
32,626 |
| Sheridan John F | PRESIDENT & CEO |
Aug 15 '26 |
Option Exercise |
0.00 |
15,916 |
0 |
165,315 |
| Vosseller Leigh | EVP & CHIEF FINANCIAL OFFICER |
Aug 15 '26 |
Option Exercise |
0.00 |
4,120 |
0 |
52,982 |
| Morrison Susan | EVP & Chief Admin. Officer |
Aug 15 '26 |
Option Exercise |
0.00 |
2,827 |
0 |
53,283 |
| Kyrillos Jean-Claude | EVP & Chief Operating Officer |
Jul 15 '26 |
Option Exercise |
0.00 |
3,636 |
0 |
31,741 |
| MARK NOVARA | Officer |
Jun 17 '26 |
Proposed Sale |
16.69 |
361 |
6,025 |
0 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):